Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fuji
Citi
Accenture
Federal Trade Commission
US Department of Justice
Cantor Fitzgerald
Cerilliant
Queensland Health
Medtronic

Generated: January 16, 2018

DrugPatentWatch Database Preview

Vorinostat - Generic Drug Details

« Back to Dashboard

What are the generic sources for vorinostat and what is the scope of vorinostat freedom to operate?

Vorinostat
is the generic ingredient in one branded drug marketed by Merck and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vorinostat has one hundred and thirty-one patent family members in thirty-five countries.

There are two drug master file entries for vorinostat. One supplier is listed for this compound.
Pharmacology for vorinostat

US Patents and Regulatory Information for vorinostat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for vorinostat

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,148,257 Methods of treating mesothelioma with suberoylanilide hydroxamic acid ➤ Subscribe
7,375,137 Methods of treating cancer with HDAC inhibitors ➤ Subscribe
8,288,440 Formulations of suberoylanilide hydroxamic acid and methods for producing same ➤ Subscribe
7,847,122 Polymorphs of suberoylanilide hydroxamic acid ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for vorinostat

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Colorcon
Covington
Moodys
Queensland Health
Argus Health
Federal Trade Commission
Cipla
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot